Fig. 2: BRD-810 has anticancer efficacy over a broad range of cancer types in vitro. | Nature Cancer

Fig. 2: BRD-810 has anticancer efficacy over a broad range of cancer types in vitro.

From: BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models

Fig. 2

a, Antiproliferative IC50 values from dose–response curves generated by exposing over n = 700 barcoded cancer cell lines ordered by cancer type to increasing doses of BRD-810 for 5 days (PRISM screen; each dot is the BRD-810 IC50 for one cell line and represents one measurement; black lines indicate the median per cancer type). b, Unbiased, genome-wide gene expression correlative to drug activity determined using Bayesian variable selection methods; the posterior mean regression coefficients are plotted against the Pearson correlation between each feature and the AUC of 700 cell lines (n = 700 cell lines; error bars represent the 95% confidence interval).

Source data

Back to article page